Human Genome Sciences

(HGSI)

reported positive early safety and efficacy results on its drug Albuferon for chronic hepatitis C.

Interim results at 12 weeks showed that patients with genotype 1 chronic hepatitis C who received the drug, in combination with ribavirin, missed fewer work days than people taking the commonly used treatment pegylated interferon alpha.

The Albuferon group also reported better quality of life scores as measured by a health survey, Human Genome said.

"This result was observed in both the physical and mental component summary measures," said David Stump, head of Human Genome's drug development. The mental health findings "suggest significantly less impairment of psychological well-being across the Albuferon treatment groups," he added.

The trial involved patients who hadn't received prior treatment regimens with interferon alpha.

Shares of Human Genome were up 2% to $12.79 Monday.